HDAC6 Antibody

1. This review delves into the HDACs, their inhibitors, and recent advancements in HDAC6 inhibitors, their mechanisms of action, and their role in lymphoproliferative disorders. PMID: 30096875
2. Mycobacterium tuberculosis infection disrupts HDAC6/HDAC11 levels, inducing IL-10 expression in macrophages. PMID: 29523311
3. Inhibition of histone deacetylase 6 (HDAC6) enhances the radiosensitivity of glioma stem cells (GSCs) by inactivating the sonic hedgehog protein (SHH)/glioma-associated oncogene homolog 1 (Gli1) pathway. PMID: 29222038
4. Silencing cortactin (CTTN) in megakaryocytes (MK) phenocopies histone deacetylase 6 (HDAC6) inactivation, and knockdown leads to a significant defect in proplatelet formation (PPF). PMID: 29176689
5. Adequate expression of Icer and adipocyte function requires Hdac5 and Hdac6 expression. Altered adipose expression of these two Hdacs in obesity due to hypoxia may contribute to the development of metabolic abnormalities. PMID: 27900262
6. This study reports that HDAC6 is involved in reactive oxygen species-NF-kappaB signaling pathways related to pro-inflammatory cytokine expression. PMID: 29414656
7. DTBP presents a promising lead structure for developing HDAC6 inhibitors, with improved specificity achieved by modifying the cap group. This study suggests, for the first time, that the anticancer activity of DTBP stems from inhibiting HDAC6 activity. PMID: 29427610
8. This report, to our knowledge, is the first to describe an HDAC6 selective inhibitor containing a hydrazide ZBG. Its ability to passively cross the blood-brain barrier (BBB), as observed through PAMPA assays, and its low cytotoxicity in vitro, suggest its potential for drug development. PMID: 27404291
9. We observed an homologous-recombination deficiency (HRD)-associated level of HDAC6 overexpression, supporting a potential role for the effectiveness of HDAC inhibitor treatment in HRD tumors characterized by low levels of H4 lysine acetylation. PMID: 28866885
10. High expression of HDAC6 is associated with chondrosarcoma. PMID: 28586053
11. HDAC6, primarily a cytoplasmic deacetylase, mediates TGF-beta1-induced EMT in human lung cancer cells via activation of Notch1. PMID: 27499032
12. Results confirm histone deacetylase 9 (HDAC9) as a major risk gene for large artery stroke with an association in the 3'-UTR. PMID: 28265093
13. Deletion or inhibition of the cytoplasmic shuttling factor HDAC6 suppressed neuritic tau bead formation in neurons. PMID: 28854366
14. At the recommended phase II dose of ricolinostat of 160 mg daily, the combination with bortezomib and dexamethasone is safe, well-tolerated, and active, suggesting that selective inhibition of HDAC6 is a promising approach to multiple myeloma therapy. PMID: 28053023
15. Increased HDAC6 expression is associated with renal cell carcinoma. PMID: 28128740
16. Our work shows that RanBPM, along with the CTLH complex, associates with HDAC6 and restricts cell migration through inhibition of HDAC6 activity. This study reveals a novel function for the CTLH complex and suggests that it might have a tumor suppressive role in restricting HDAC6 oncogenic properties. PMID: 28668087
17. Results provide evidence that HDAC6 mediates the HIV-1 Tat-induced expression of chemokines by regulating reactive oxygen species-Nox2-based NADPH oxidase pathways in astrocytes. Furthermore, there is crosstalk between HDAC6 and NADPH oxidase in HIV-1 Tat-induced chemokine expression in astrocytes. PMID: 28499252
18. The development of this ACY-1215-resistant cell line has provided valuable insights into the mechanistic role of HDAC6 in lymphoma and offered a novel method to identify rational synergistic drug combinations. PMID: 27993968
19. rhTGF-beta1 affects the sensitivity of human osteoblasts to mechanical stimuli by damaging the microtubule structure of primary cilia in an HDAC6-dependent manner. PMID: 28271209
20. In conclusion, HDAC6 might enhance the progression of aggressive melanoma cells through interactions with PTPN1, independent of its histone-modifying activity. PMID: 29278704
21. Using motor neurons derived from induced pluripotent stem cells from patients with amyotrophic lateral sclerosis and FUS mutations, axonal transport defects could be successfully rescued by HDAC6 inhibitors or silencing HDAC6. PMID: 29021520
22. Data show that selective histone deacetylase 6 (HDAC6) inhibition or knockdown of HDAC6 expression was able to prevent caspase 3 activation in lung endothelial cells and maintain lung endothelial cell-cell junctions. PMID: 27419634
23. The HDAC6 inhibitor Tubacin induces the release of CD133(+) extracellular vesicles from cancer cells. PMID: 28452069
24. MicroRNA-22 promotes osteogenic differentiation of human periodontal ligament stem cells by targeting HDAC6. PMID: 28195408
25. A decrease in HDAC6 expression caused by Helicobacter pylori infection is associated with oncogenic transformation in gastric cancer. PMID: 28700998
26. These results suggest that HDAC1 and HDAC6 may play a role in clear cell renal cell carcinoma biology. PMID: 27506904
27. Genetic abrogation of HDAC6 in primary melanoma samples and cell lines down-regulates the expression of PD-L1, a significant co-stimulatory molecule expressed in cancer cells, which activates the inhibitory regulatory pathway PD-1 in T-cells. PMID: 26775640
28. Activation appears to be a key survival mechanism for HDAC6 inhibitor treatment. PMID: 27362804
29. ARID1A mutation inactivates the apoptosis-promoting function of p53 by upregulating HDAC6, indicating that pharmacological inhibition of HDAC6 is a therapeutic strategy for ARID1A-mutated cancers. PMID: 28737768
30. 7-amino-4-methylcoumarin did not affect acetyllysine preference in a multiply acetylated substrate. In contrast, AMC significantly enhanced KDAC6 substrate affinity, greatly reduced Sirt1 activity, eliminated the substrate sequence specificity of KDAC4, and had no consistent effect with KDAC8 substrates. PMID: 28749131
31. Deacetylation of MST1 mediated by HBXIP-enhanced HDAC6 results in MST1 degradation in a chaperone-mediated autophagy (CMA) manner, promoting breast cancer growth. PMID: 26657153
32. This study suggests that HDAC4 and HDAC6 act as guardians of irradiation-induced DNA damage and stemness, thus promoting radioresistance in glioblastoma cells. PMID: 28342984
33. These results indicate overlapping and distinct functions of HDAC6 and SIRT2. PMID: 27311481
34. Results provide evidence that HDAC6 could regulate HMGN2 acetylation levels and binding to Stat5a-responsive promoters, and therefore, Stat5a transcriptional activity in breast cancer cells. PMID: 27358110
35. HDAC6 promotes glioblastoma cell proliferation and confers resistance to temozolomide. PMID: 27267806
36. The authors characterized the histone deacetylase 6-interacting proteins in LNCaP metastatic prostate cancer cells and found that histone deacetylase 6 interacts with proteins involved in several cellular processes, including autophagy. PMID: 26643866
37. HDAC6 may represent an optimal target for future immunosuppressant therapeutics, particularly in transplantation. PMID: 27222932
38. A combination regimen of bortezomib and the histone deacetylase inhibitor trichostatin A abolished HDAC6 activity and decreased autophagy induction while significantly enhancing bortezomib-induced apoptosis in HNSCC cells. PMID: 27369083
39. This review highlights current data illustrating the complexity and importance of HDAC6 in viral pathogenesis. [review] PMID: 27959772
40. Systemic lupus erythematosus patients had higher methylation in the HDAC6 promoter and lower HDAC6 mRNA expression than the controls. These changes may be related to the susceptibility of SLE. However, they are not associated with the disease activity of SLE. PMID: 26461065
41. Cutaneous T-cell lymphoma (CTCL) pathogenesis remains unknown, and there are no curative therapies. Our findings not only demonstrate a critical role for IL15-mediated inflammation in cutaneous T-cell lymphomagenesis but also uncover a new oncogenic regulatory loop in CTCL involving IL15, HDAC1, HDAC6, and miR-21 that shows differential sensitivity to isotype-specific HDAC inhibitors. PMID: 27422033
42. HDAC6 confers resistance to vemurafenib in BRAF-mutant melanoma cells. PMID: 28035401
43. The inhibition of HDAC6 may be a promising strategy for the treatment of lung adenocarcinoma. PMID: 27221381
44. Data show that expressions of histone deacetylase 6 protein (HDAC6) and c-myc protein are increased in fibroblasts transformed with activated K-ras protein. PMID: 26848526
45. Overexpression of HDAC6 confers non-small cell lung cancer resistance to sorafenib. PMID: 27090797
46. These data indicate that HDAC6, and acetylated alpha-tubulin, are important regulators of adipocyte differentiation. PMID: 26363102
47. HDAC5 and HDAC6 were highly expressed in melanoma cells but exhibited low expression levels in normal skin cells. PMID: 26747087
48. This study found that HDAC6 was significantly down-regulated in hepatocellular carcinoma cells (HCC), and the low expression of HDAC6 was closely associated with a high recurrence rate in HCC patients with liver transplantation. PMID: 26086159
49. Results provide new mechanistic insights into the understanding that deacetylation of HSPA5 by HDAC6 facilitates GP78-mediated HSPA5 ubiquitination. PMID: 26119938
50. TGF-beta increased the activity of HDAC6 without affecting its expression levels. PMID: 26763233

Show More

Hide All

HGNC: 14064

OMIM: 300272

KEGG: hsa:10013

STRING: 9606.ENSP00000334061

UniGene: Hs.6764